
Feb 21 (Reuters) - Novo Nordisk A/S NOVOb.CO:
FDA DECLARES WEGOVY® AND OZEMPIC® SHORTAGE IS OVER AND THAT NOVO NORDISK IS FULLY MEETING OR EXCEEDING NATIONWIDE DEMAND FOR ALL DOSES
NOVO NORDISK: ALL DOSES OF FDA-APPROVED SEMAGLUTIDE MEDICINES ARE BEING CONTINUOUSLY SHIPPED, MEETING OR EXCEEDING EXPECTED U.S. DEMAND
NOVO NORDISK - FDA'S DECISION MEANS THAT MAKING OR SELLING KNOCKOFF COMPOUNDED DRUG THAT IS ESSENTIALLY A COPY OF OZEMPIC OR WEGOVY IS ILLEGAL
Source text: ID:nPn3ClKD7a
Further company coverage: [NOVOb.CO]